We are live on ! Find out more
GANX icon

Gain Therapeutics
GANX

16 hedge funds and large institutions have $3.87M invested in Gain Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

0% more funds holding

Funds holding: 16 → 16 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.73% less ownership

Funds ownership: 9.78% → 9.05% (-0.73%)

65% less capital inflows, than outflows

Capital inflows: $179K | Capital outflows: $509K

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$114K
2
BlackRock
BlackRock
New York
+$44.5K
3
Cannell Capital
Cannell Capital
Wyoming
+$9.49K
4
UBS Group
UBS Group
Switzerland
+$7.97K
5
Hoey Investments
Hoey Investments
Pennsylvania
+$1.72K

Top Sellers

Rank Fund Capital Flow
1
TI
Telemetry Investments
New York
-$276K
2
Veritable
Veritable
Delaware
-$103K
3
Jane Street
Jane Street
New York
-$48K
4
Millennium Management
Millennium Management
New York
-$44K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$37.9K

GANX Hedge Fund Activity: Q2 2022 in Review

16 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q2 2022, worth a combined $3.87M — down 19% from $4.75M a quarter earlier.

Fund positioning in GANX was balanced in Q2 2022: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 3 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $114K. The largest seller was Telemetry Investments, cutting an estimated $276K.

  • 16 institutional investors held Gain Therapeutics (GANX) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $3.87M of Gain Therapeutics stock for Q2 2022, down 19% quarter-over-quarter.
  • 3 funds opened new Gain Therapeutics positions in Q2 2022 and 3 closed out, a net change of 0 holders.
  • The largest Gain Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $114K added.
  • The largest Gain Therapeutics seller in Q2 2022 was Telemetry Investments, an estimated $276K sold.

Based on aggregated 13F filings for Q2 2022.